Prominent Targets for Cancer Care: Immunotherapy Perspective

Mehul      Patel; Aashka      Thakkar; Priya      Bhatt; Umang      Shah; Ashish      Patel; Nilay      Solanki; Swayamprakash      Patel; Sandip      Patel; Karan      Gandhi; Bhavesh      Patel
Abstract

Objective: Recent scientific advances have expanded insight into the immune system and its response to malignant cells. In the past few years, immunotherapy has attained a hallmark for cancer treatment, especially for patients suffering from the advanced-stage disease. Modulating the immune system by blocking various immune checkpoint receptor proteins through monoclonal antibodies has improved cancer patients' survival rates.
Methods: The scope of this review spans from 1985 to the present day. Many journals, books, and theses have been used to gather data, as well as Internet-based information such as Wiley, PubMed, Google Scholar, ScienceDirect, EBSCO, SpringerLink, and Online electronic journals.
Key Findings: Current review elaborates on the potential inhibitory and stimulatory checkpoint pathways which are emerged and have been tested in various preclinical models, clinical trials, and practices. Twenty-odd such significant checkpoints are identified and discussed in the present work.
Conclusion: A large number of ongoing studies reveal that combination therapies that target more than one signaling pathway may become effective in order to maximize efficacy and minimize toxicity. Moreover, these immunotherapy targets can be a part of integrated therapeutic strategies in addition to classical approaches. It may become a paradigm shift as a promising strategy for cancer treatment.
Graphical Abstract

[1]
Thomas S, Quinn BA, Das SK, et al. Targeting the Bcl-2 family for cancer therapy. Expert Opin Ther Targets  2013; 17(1): 61-75.
 [http://dx.doi.org/10.1517/14728222.2013.733001] [PMID:  23173842]

[2]
Steck E, Bertram H, Abel R, Chen B, Winter A, Richter W. Induction of intervertebral disc-like cells from adult mesenchymal stem cells. Stem Cells  2005; 23(3): 403-11.
 [http://dx.doi.org/10.1634/stemcells.2004-0107] [PMID:  15749935]

[3]
Parsa N. Environmental factors inducing human cancers. Iran J Public Health  2012; 41(11): 1-9.
 [PMID:  23304670]

[4]
Jacob L, Freyn M, Kalder M, Dinas K, Kostev K. Impact of tobacco smoking on the risk of developing 25 different cancers in the UK: A retrospective study of 422,010 patients followed for up to 30 years. Oncotarget  2018; 9(25): 17420-9.
 [http://dx.doi.org/10.18632/oncotarget.24724] [PMID:  29707117]

[5]
Momenimovahed Z, Salehiniya H. Epidemiological characteristics of and risk factors for breast cancer in the world. Breast Cancer  2019; 11: 151-64.
 [http://dx.doi.org/10.2147/BCTT.S176070] [PMID:  31040712]

[6]
Arem H, Loftfield E. Cancer epidemiology: A survey of modifiable risk factors for prevention and survivorship. Am J Lifestyle Med  2018; 12(3): 200-10.
 [http://dx.doi.org/10.1177/1559827617700600] [PMID:  30202392]

[7]
Cleeland CS. Cancer-related symptoms. Semin Radiat Oncol  2000; 10(3): 175-90.
 [http://dx.doi.org/10.1053/srao.2000.6590] [PMID:  11034629]

[8]
Arruebo M, Vilaboa N, Sáez-Gutierrez B, et al. Assessment of the evolution of cancer treatment therapies. Cancers (Basel)  2011; 3(3): 3279-330.
 [http://dx.doi.org/10.3390/cancers3033279] [PMID:  24212956]

[9]
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin  2018; 68(6): 394-424.
 [http://dx.doi.org/10.3322/caac.21492] [PMID:  30207593]

[10]
Liu M, Guo F. Recent updates on cancer immunotherapy. Precis Clin Med  2018; 1(2): 65-74.
 [http://dx.doi.org/10.1093/pcmedi/pby011] [PMID:  30687562]

[11]
Disis ML. Mechanism of action of immunotherapy. Semin Oncol  2014; 41(S5): S3-S13.
 [http://dx.doi.org/10.1053/j.seminoncol.2014.09.004] [PMID:  25438997]

[12]
Bai RL, Chen NF, Li LY, Cui JW. A brand new era of cancer immunotherapy: Breakthroughs and challenges. Chin Med J (Engl)  2021; 134(11): 1267-75.
 [http://dx.doi.org/10.1097/CM9.0000000000001490] [PMID:  34039862]

[13]
Ratajczak W. Niedźwiedzka-Rystwej P, Tokarz-Deptuła B, Deptuła W. Immunological memory cells. Cent Eur J Immunol  2018; 43(2): 194-203.
 [http://dx.doi.org/10.5114/ceji.2018.77390] [PMID:  30135633]

[14]
Yan S, Zhao P, Yu T, Gu N. Current applications and future prospects of nanotechnology in cancer immunotherapy. Cancer Biol Med  2019; 16(3): 487-97.
 [http://dx.doi.org/10.20892/j.issn.2095-3941.2018.0493] [PMID:  31565479]

[15]
Karmakar S, Dhar R, Seethy A, et al. Cancer immunotherapy: Recent advances and challenges. J Cancer Res Ther  2021; 17(4): 834-44.
 [http://dx.doi.org/10.4103/jcrt.JCRT_1241_20] [PMID:  34528529]

[16]
Long J, Qi Z, Rongxin Z. PD-1/PD-L1 pathway blockade works as an effective and practical therapy for cancer immunotherapy. Cancer Biol Med  2018; 15(2): 116-23.
 [http://dx.doi.org/10.20892/j.issn.2095-3941.2017.0086] [PMID:  29951336]

[17]
Kythreotou A, Siddique A, Mauri FA, Bower M, Pinato DJ. Pd-L1. J Clin Pathol  2018; 71(3): 189-94.
 [http://dx.doi.org/10.1136/jclinpath-2017-204853] [PMID:  29097600]

[18]
Meng X, Huang Z, Teng F, Xing L, Yu J. Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy. Cancer Treat Rev  2015; 41(10): 868-76.
 [http://dx.doi.org/10.1016/j.ctrv.2015.11.001] [PMID:  26589760]

[19]
Jiang Y, Chen M, Nie H, Yuan Y. PD-1 and PD-L1 in cancer immunotherapy: Clinical implications and future considerations. Hum Vaccin Immunother  2019; 15(5): 1111-22.
 [http://dx.doi.org/10.1080/21645515.2019.1571892] [PMID:  30888929]

[20]
Wei R, Guo L, Wang Q, Miao J, Kwok HF, Lin Y. Targeting PD-L1 Protein: Translation, modification and transport. Curr Protein Pept Sci  2018; 20(1): 82-91.
 [http://dx.doi.org/10.2174/1389203719666180928105632] [PMID:  30264678]

[21]
Zou W, Wolchok JD, Chen L, Weiping Z, Jedd DW, Lieping C. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy. Sci Transl Med  2016; 8(328): 1-34.
 [http://dx.doi.org/10.1126/scitranslmed.aad7118] [PMID:  26936508]

[22]
Alsaab HO, Sau S, Alzhrani R, et al. PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. Front Pharmacol  2017; 8(AUG): 561.
 [http://dx.doi.org/10.3389/fphar.2017.00561] [PMID:  28878676]

[23]
Akinleye A, Rasool Z. Immune checkpoint inhibitors of PD-L1 as cancer therapeutics. J Hematol Oncol  2019; 12(1): 92.
 [http://dx.doi.org/10.1186/s13045-019-0779-5] [PMID:  31488176]

[24]
Huang G, Sun X, Liu D, et al. The efficacy and safety of anti-PD-1/PD-L1 antibody therapy versus docetaxel for pretreated advanced NSCLC: a meta-analysis. Oncotarget  2018; 9(3): 4239-48.
 [http://dx.doi.org/10.18632/oncotarget.23279] [PMID:  29423118]

[25]
Gong J, Chehrazi-Raffle A, Reddi S, Salgia R. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: A comprehensive review of registration trials and future considerations. J Immunother Cancer  2018; 6(1): 8.
 [http://dx.doi.org/10.1186/s40425-018-0316-z] [PMID:  29357948]

[26]
Verhagen J, Sabatos CA, Wraith DC. The role of CTLA-4 in immune regulation. Immunol Lett  2008; 115(1): 73-4.
 [http://dx.doi.org/10.1016/j.imlet.2007.10.010] [PMID:  18035425]

[27]
Brunet JF, Denizot F, Luciani MF, et al. A new member of the immunoglobulin superfamily-CTLA-4. Nature  1987; 328(6127): 267-70.
 [http://dx.doi.org/10.1038/328267a0] [PMID:  3496540]

[28]
McCoy KD, Le Gros G. The role of CTLA-4 in the regulation of T cell immune responses. Immunol Cell Biol  1999; 77(1): 1-10.
 [http://dx.doi.org/10.1046/j.1440-1711.1999.00795.x] [PMID:  10101680]

[29]
Eagar TN, Karandikar NJ, Bluestone JA, Miller SD. The role of CTLA-4 in induction and maintenance of peripheral T cell tolerance. Eur J Immunol  2002; 32(4): 972-81.
 [http://dx.doi.org/10.1002/1521-4141(200204)32:4<972::AID-IMMU972>3.0.CO;2-M] [PMID:  11920563]

[30]
Tai X, Van Laethem F, Pobezinsky L, et al. Basis of CTLA-4 function in regulatory and conventional CD4+ T cells. Blood  2012; 119(22): 5155-63.
 [http://dx.doi.org/10.1182/blood-2011-11-388918] [PMID:  22403258]

[31]
Sansom DM. CD28, CTLA-4 and their ligands: who does what and to whom? Immunology  2000; 101(2): 169-77.
 [http://dx.doi.org/10.1046/j.1365-2567.2000.00121.x] [PMID:  11012769]

[32]
Rowshanravan B, Halliday N, Sansom DM. CTLA-4: A moving target in immunotherapy. Blood  2018; 131(1): 58-67.
 [http://dx.doi.org/10.1182/blood-2017-06-741033] [PMID:  29118008]

[33]
Podojil JR, Miller SD. Potential targeting of B7-H4 for the treatment of cancer. Immunol Rev  2017; 276(1): 40-51.
 [http://dx.doi.org/10.1111/imr.12530] [PMID:  28258701]

[34]
Simone R, Pesce G, Antola P, et al. The soluble form of CTLA-4from serum of patients with autoimmune diseases regulates T-Cell responses. Biomed Res Int 2014; 2014
 [http://dx.doi.org/10.1155/2014/215763]

[35]
Engelhardt JJ, Sullivan TJ, Allison JP. CTLA-4 overexpression inhibits T cell responses through a CD28-B7-dependent mechanism. J Immunol  2006; 177(2): 1052-61.
 [http://dx.doi.org/10.4049/jimmunol.177.2.1052] [PMID:  16818761]

[36]
Chen W, Jin W, Wahl SM. Engagement of cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) induces transforming growth factor β (TGF-β) production by murine CD4(+) T cells. J Exp Med  1998; 188(10): 1849-57.
 [http://dx.doi.org/10.1084/jem.188.10.1849] [PMID:  9815262]

[37]
Wolchok JD, Saenger Y. The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation. Oncologist  2008; 13(S4) (Suppl. 4): 2-9.
 [http://dx.doi.org/10.1634/theoncologist.13-S4-2] [PMID:  19001145]

[38]
Vandenborre K, Van Gool SW, Kasran A, Ceuppens JL, Boogaerts MA, Vandenberghe P. Interaction of CTLA-4 (CD152) with CD80 or CD86 inhibits human T-cell activation. Immunology  1999; 98(3): 413-21.
 [http://dx.doi.org/10.1046/j.1365-2567.1999.00888.x] [PMID:  10583602]

[39]
Liu Y, Zheng P. How does an anti-CTLA-4 antibody promote cancer immunity? Trends Immunol  2018; 39(12): 953-6.
 [http://dx.doi.org/10.1016/j.it.2018.10.009] [PMID:  30497614]

[40]
Hurst JH. Cancer immunotherapy innovator James Allison receives the 2015 Lasker~DeBakey Clinical Medical Research Award. J Clin Invest  2015; 125(10): 3732-6.
 [http://dx.doi.org/10.1172/JCI84236] [PMID:  26345422]

[41]
Tian X, Zhang A, Qiu C, et al. The upregulation of LAG-3 on T cells defines a subpopulation with functional exhaustion and correlates with disease progression in HIV-infected subjects. J Immunol  2015; 194(8): 3873-82.
 [http://dx.doi.org/10.4049/jimmunol.1402176] [PMID:  25780040]

[42]
Long L, Zhang X, Chen F, et al. The promising immune checkpoint LAG-3: from tumor microenvironment to cancer immunotherapy. Genes Cancer  2018; 9(5-6): 176-89.
 [http://dx.doi.org/10.18632/genesandcancer.180] [PMID:  30603054]

[43]
Shan C, Li X, Zhang J. Progress of immune checkpoint LAG 3 in immunotherapy (Review). Oncol Lett  2020; 20(5): 1.
 [http://dx.doi.org/10.3892/ol.2020.12070] [PMID:  32963613]

[44]
Gun SY, Lee SWL, Sieow JL, Wong SC. Targeting immune cells for cancer therapy. Redox Biol  2019; 25(March): 101174.
 [http://dx.doi.org/10.1016/j.redox.2019.101174] [PMID:  30917934]

[45]
Anderson AC, Joller N, Kuchroo VK. Lag-3, Tim-3, and TIGIT: Co-inhibitory receptors with specialized functions in immune regulation. immunity, NIH public access 44, 989–1004.Ag-3, Tim-3, and TIGIT: Co-inhibitory receptors with specia. Immunity  2016; 44(5): 989-1004.
 [http://dx.doi.org/10.1016/j.immuni.2016.05.001] [PMID:  27192565]

[46]
Maruhashi T, Okazaki I, Sugiura D, et al. LAG-3 inhibits the activation of CD4+ T cells that recognize stable pMHCII through its conformation-dependent recognition of pMHCII. Nat Immunol  2018; 19(12): 1415-26.
 [http://dx.doi.org/10.1038/s41590-018-0217-9] [PMID:  30349037]

[47]
Hemon P, Jean-Louis F, Ramgolam K, et al. MHC class II engagement by its ligand LAG-3 (CD223) contributes to melanoma resistance to apoptosis. J Immunol  2011; 186(9): 5173-83.
 [http://dx.doi.org/10.4049/jimmunol.1002050] [PMID:  21441454]

[48]
Huang RY, Eppolito C, Lele S, Shrikant P, Matsuzaki J, Odunsi K. LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer model. Oncotarget  2015; 6(29): 27359-77.
 [http://dx.doi.org/10.18632/oncotarget.4751] [PMID:  26318293]

[49]
Workman CJ, Cauley LS, Kim IJ, Blackman MA, Woodland DL, Vignali DAA. Lymphocyte activation gene-3 (CD223) regulates the size of the expanding T cell population following antigen activation in vivo. J Immunol  2004; 172(9): 5450-5.
 [http://dx.doi.org/10.4049/jimmunol.172.9.5450] [PMID:  15100286]

[50]
Panda A, Rosenfeld JA, Singer EA, Bhanot G, Ganesan S. Genomic and immunologic correlates of LAG-3 expression in cancer. OncoImmunology  2020; 9(1): 1756116.
 [http://dx.doi.org/10.1080/2162402X.2020.1756116] [PMID:  32923111]

[51]
Romano E, Michielin O, Voelter V, et al. MART-1 peptide vaccination plus IMP321 (LAG-3Ig fusion protein) in patients receiving autologous PBMCs after lymphodepletion: results of a Phase I trial. J Transl Med  2014; 12(1): 97.
 [http://dx.doi.org/10.1186/1479-5876-12-97] [PMID:  24726012]

[52]
Solinas C, Gu-Trantien C, Willard-Gallo K. The rationale behind targeting the ICOS-ICOS ligand costimulatory pathway in cancer immunotherapy. ESMO Open  2020; 5(1): e000544.
 [http://dx.doi.org/10.1136/esmoopen-2019-000544] [PMID:  32516116]

[53]
Grosso JF, Kelleher CC, Harris TJ, et al. LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems. J Clin Invest  2007; 117(11): 3383-92.
 [http://dx.doi.org/10.1172/JCI31184] [PMID:  17932562]

[54]
Xu F, Liu J, Liu D, et al. LSECtin expressed on melanoma cells promotes tumor progression by inhibiting antitumor T-cell responses. Cancer Res  2014; 74(13): 3418-28.
 [http://dx.doi.org/10.1158/0008-5472.CAN-13-2690] [PMID:  24769443]

[55]
Mujib S, Jones RB, Lo C, et al. Antigen-independent induction of Tim-3 expression on human T cells by the common γ-chain cytokines IL-2, IL-7, IL-15, and IL-21 is associated with proliferation and is dependent on the phosphoinositide 3-kinase pathway. J Immunol  2012; 188(8): 3745-56.
 [http://dx.doi.org/10.4049/jimmunol.1102609] [PMID:  22422881]

[56]
Das M, Zhu C, Kuchroo VK. Tim-3 and its role in regulating anti-tumor immunity. Immunol Rev  2017; 276(1): 97-111.
 [http://dx.doi.org/10.1111/imr.12520] [PMID:  28258697]

[57]
Han G, Chen G, Shen B, Li Y. Tim-3: an activation marker and activation limiter of innate immune cells. Front Immunol  2013; 4(DEC): 449.
 [http://dx.doi.org/10.3389/fimmu.2013.00449] [PMID:  24339828]

[58]
Meyers JH, Sabatos CA, Chakravarti S, Kuchroo VK. The TIM gene family regulates autoimmune and allergic diseases. Trends Mol Med  2005; 11(8): 362-9.
 [http://dx.doi.org/10.1016/j.molmed.2005.06.008] [PMID:  16002337]

[59]
Yoneda A, Jinushi M. T cell immunoglobulin domain and mucin domain-3 as an emerging target for immunotherapy in cancer management. ImmunoTargets Ther  2013; 2: 135-41.
 [PMID:  27471694]

[60]
Rodriguez-Manzanet R, DeKruyff R, Kuchroo VK, Umetsu DT. The costimulatory role of TIM molecules. Immunol Rev  2009; 229(1): 259-70.
 [http://dx.doi.org/10.1111/j.1600-065X.2009.00772.x] [PMID:  19426227]

[61]
Freeman GJ, Casasnovas JM, Umetsu DT, DeKruyff RH. TIM genes: a family of cell surface phosphatidylserine receptors that regulate innate and adaptive immunity. Immunol Rev  2010; 235(1): 172-89.
 [http://dx.doi.org/10.1111/j.0105-2896.2010.00903.x] [PMID:  20536563]

[62]
Du W, Yang M, Turner A, et al. TIM-3 as a target for cancer immunotherapy and mechanisms of action. Int J Mol Sci  2017; 18(3): 645.
 [http://dx.doi.org/10.3390/ijms18030645] [PMID:  28300768]

[63]
Zhu C, Anderson AC, Schubart A, et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol  2005; 6(12): 1245-52.
 [http://dx.doi.org/10.1038/ni1271] [PMID:  16286920]

[64]
Elahi S, Niki T, Hirashima M, Horton H. Galectin-9 binding to Tim-3 renders activated human CD4+ T cells less susceptible to HIV-1 infection. Blood  2012; 119(18): 4192-204.
 [http://dx.doi.org/10.1182/blood-2011-11-389585] [PMID:  22438246]

[65]
Jiang Y, Li Y, Zhu B. T-cell exhaustion in the tumor microenvironment. Cell Death Dis  2015; 6(6): e1792.
 [http://dx.doi.org/10.1038/cddis.2015.162] [PMID:  26086965]

[66]
Liu Y, Gao LF, Liang XH, Ma CH. Role of Tim-3 in hepatitis B virus infection: An overview. World J Gastroenterol  2016; 22(7): 2294-303.
 [http://dx.doi.org/10.3748/wjg.v22.i7.2294] [PMID:  26900291]

[67]
He Y, Cao J, Zhao C, Li X, Zhou C, Hirsch F. TIM-3, a promising target for cancer immunotherapy. OncoTargets Ther  2018; 11: 7005-9.
 [http://dx.doi.org/10.2147/OTT.S170385] [PMID:  30410357]

[68]
Zhou E, Huang Q, Wang J, et al. Up-regulation of Tim-3 is associated with poor prognosis of patients with colon cancer. Int J Clin Exp Pathol  2015; 8(7): 8018-27.
 [PMID:  26339368]

[69]
Acharya N, Sabatos-Peyton C, Anderson AC, Anderson AC, Anderson AC. Tim-3 finds its place in the cancer immunotherapy landscape. J Immunother Cancer  2020; 8(1): e000911.
 [http://dx.doi.org/10.1136/jitc-2020-000911] [PMID:  32601081]

[70]
Anderson AC. Tim-3: An emerging target in the cancer immunotherapy landscape. Cancer Immunol Res  2014; 2(5): 393-8.
 [http://dx.doi.org/10.1158/2326-6066.CIR-14-0039] [PMID:  24795351]

[71]
Yu X, Harden K, C Gonzalez L, et al. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nat Immunol  2009; 10(1): 48-57.
 [http://dx.doi.org/10.1038/ni.1674] [PMID:  19011627]

[72]
Levin SD, Taft DW, Brandt CS, et al. Vstm3 is a member of the CD28 family and an important modulator of T-cell function. Eur J Immunol  2011; 41(4): 902-15.
 [http://dx.doi.org/10.1002/eji.201041136] [PMID:  21416464]

[73]
Harjunpää H, Guillerey C. TIGIT as an emerging immune checkpoint. Clin Exp Immunol  2020; 200(2): 108-19.
 [http://dx.doi.org/10.1111/cei.13407] [PMID:  31828774]

[74]
Kurtulus S, Sakuishi K, Ngiow SF, et al. TIGIT predominantly regulates the immune response via regulatory T cells. J Clin Invest  2015; 125(11): 4053-62.
 [http://dx.doi.org/10.1172/JCI81187] [PMID:  26413872]

[75]
Manieri NA, Chiang EY, Grogan JL. TIGIT: A key inhibitor of the cancer immunity cycle. Trends Immunol  2017; 38(1): 20-8.
 [http://dx.doi.org/10.1016/j.it.2016.10.002] [PMID:  27793572]

[76]
Sanchez-Correa B, Valhondo I, Hassouneh F, et al. DNAM-1 and the TIGIT/PVRIG/TACTILE Axis: Novel immune checkpoints for natural killer cell-based cancer immunotherapy. Cancers   2019; 11(6): 877.
 [http://dx.doi.org/10.3390/cancers11060877] [PMID:  31234588]

[77]
Molfetta R, Zitti B, Lecce M, et al. CD155: A multi-functional molecule in tumor progression. Int J Mol Sci  2020; 21(3): 922.
 [http://dx.doi.org/10.3390/ijms21030922] [PMID:  32019260]

[78]
Tahara-Hanaoka S, Shibuya K, Onoda Y, et al. Functional characterization of DNAM-1 (CD226) interaction with its ligands PVR (CD155) and nectin-2 (PRR-2/CD112). Int Immunol  2004; 16(4): 533-8.
 [http://dx.doi.org/10.1093/intimm/dxh059] [PMID:  15039383]

[79]
Stengel KF, Harden-Bowles K, Yu X, et al. Structure of TIGIT immunoreceptor bound to poliovirus receptor reveals a cell–cell adhesion and signaling mechanism that requires cis-trans receptor clustering. Proc Natl Acad Sci USA  2012; 109(14): 5399-404.
 [http://dx.doi.org/10.1073/pnas.1120606109] [PMID:  22421438]

[80]
Chauvin JM, Zarour HM. TIGIT in cancer immunotherapy. J Immunother Cancer  2020; 8(2): e000957.
 [http://dx.doi.org/10.1136/jitc-2020-000957] [PMID:  32900861]

[81]
Hoteit M, Oneissi Z, Reda R, et al. Cancer immunotherapy: A comprehensive appraisal of its modes of application. Oncol Lett  2021; 22(3): 655.
 [http://dx.doi.org/10.3892/ol.2021.12916] [PMID:  34386077]

[82]
Gao J, Zheng Q, Xin N, Wang W, Zhao C. CD 155, an onco-immunologic molecule in human tumors. Cancer Sci  2017; 108(10): 1934-8.
 [http://dx.doi.org/10.1111/cas.13324] [PMID:  28730595]

[83]
Stanietsky N, Simic H, Arapovic J, et al. The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity. Proc Natl Acad Sci USA  2009; 106(42): 17858-63.
 [http://dx.doi.org/10.1073/pnas.0903474106] [PMID:  19815499]

[84]
Liu S, Zhang H, Li M, et al. Recruitment of Grb2 and SHIP1 by the ITT-like motif of TIGIT suppresses granule polarization and cytotoxicity of NK cells. Cell Death Differ  2013; 20(3): 456-64.
 [http://dx.doi.org/10.1038/cdd.2012.141] [PMID:  23154388]

[85]
Dixon KO, Schorer M, Nevin J, et al. Functional Anti-TIGIT antibodies regulate development of autoimmunity and antitumor immunity. J Immunol  2018; 200(8): 3000-7.
 [http://dx.doi.org/10.4049/jimmunol.1700407] [PMID:  29500245]

[86]
Guillerey C, Harjunpää H, Harjunpä H, et al. Brief Report IMMUNOBIOLOGY AND IMMUNOTHERAPY TIGIT Immune Checkpoint Blockade Restores CD8 1 T-Cell Immunity against Multiple Myeloma. Blood  2018; 132(16): 1689-94.
 [http://dx.doi.org/10.1182/blood-2018-01-825265] [PMID:  29986909]

[87]
Dougall WC, Kurtulus S, Smyth MJ, Anderson AC. TIGIT and CD96: New checkpoint receptor targets for cancer immunotherapy. Immunol Rev  2017; 276(1): 112-20.
 [http://dx.doi.org/10.1111/imr.12518] [PMID:  28258695]

[88]
Muller S, Victoria Lai W, Adusumilli PS, et al. V-domain Ig-containing suppressor of T-cell activation (VISTA), a potentially targetable immune checkpoint molecule, is highly expressed in epithelioid malignant pleural mesothelioma. Mod Pathol  2020; 33(2): 303-11.
 [http://dx.doi.org/10.1038/s41379-019-0364-z] [PMID:  31537897]

[89]
Lines JL, Pantazi E, Mak J, et al. VISTA is an immune checkpoint molecule for human T cells. Cancer Res  2014; 74(7): 1924-32.
 [http://dx.doi.org/10.1158/0008-5472.CAN-13-1504] [PMID:  24691993]

[90]
Wang L, Rubinstein R, Lines JL, et al. VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses. J Exp Med  2011; 208(3): 577-92.
 [http://dx.doi.org/10.1084/jem.20100619] [PMID:  21383057]

[91]
Rothlin CV, Ghosh S. Lifting the innate immune barriers to antitumor immunity. J Immunother Cancer  2020; 8(1): e000695.
 [http://dx.doi.org/10.1136/jitc-2020-000695] [PMID:  32273348]

[92]
Li N, Xu W, Yuan Y, et al. Immune-checkpoint protein VISTA critically regulates the IL-23/IL-17 inflammatory axis. Sci Rep  2017; 7(1): 1485.
 [http://dx.doi.org/10.1038/s41598-017-01411-1] [PMID:  28469254]

[93]
Wang J, Wu G, Manick B, et al. VSIG-3 as a ligand of VISTA inhibits human T-cell function. Immunology  2019; 156(1): 74-85.
 [http://dx.doi.org/10.1111/imm.13001] [PMID:  30220083]

[94]
Huang X, Zhang X, Li E, et al. VISTA: an immune regulatory protein checking tumor and immune cells in cancer immunotherapy. J Hematol Oncol  2020; 13(1): 83.
 [http://dx.doi.org/10.1186/s13045-020-00917-y] [PMID:  32600443]

[95]
Hid Cadena R, Reitsema RD, Huitema MG, et al. Decreased expression of negative immune checkpoint VISTA by CD4+ T cells facilitates T Helper 1, T Helper 17, and T follicular helper lineage differentiation in GCA. Front Immunol  2019; 10(JULY): 1638.
 [http://dx.doi.org/10.3389/fimmu.2019.01638] [PMID:  31379838]

[96]
Mulati K, Hamanishi J, Matsumura N, et al. VISTA expressed in tumour cells regulates T cell function. Br J Cancer  2019; 120(1): 115-27.
 [http://dx.doi.org/10.1038/s41416-018-0313-5] [PMID:  30382166]

[97]
Wei SC, Duffy CR, Allison JP. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov  2018; 1069-86.

[98]
Hutloff A, Dittrich AM, Beier KC, et al. ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28. Nature  1999; 397(6716): 263-6.
 [http://dx.doi.org/10.1038/16717] [PMID:  9930702]

[99]
Mahajan S, Cervera A, MacLeod M, et al. The role of ICOS in the development of CD4 T cell help and the reactivation of memory T cells. Eur J Immunol  2007; 37(7): 1796-808.
 [http://dx.doi.org/10.1002/eji.200636661] [PMID:  17549732]

[100]
McAdam AJ, Chang TT, Lumelsky AE, et al. Mouse inducible costimulatory molecule (ICOS) expression is enhanced by CD28 costimulation and regulates differentiation of CD4+ T cells. J Immunol  2000; 165(9): 5035-40.
 [http://dx.doi.org/10.4049/jimmunol.165.9.5035] [PMID:  11046032]

[101]
Vettermann C, Victor HP, Sun Y, Plewa C, Gupta S. A signaling-enhanced chimeric receptor to activate the ICOS pathway in T cells. J Immunol Methods  2015; 424: 14-9.
 [http://dx.doi.org/10.1016/j.jim.2015.04.015] [PMID:  25956037]

[102]
Vocanson M, Rozieres A, Hennino A, et al. Inducible costimulator (ICOS) is a marker for highly suppressive antigen-specific T cells sharing features of TH17/TH1 and regulatory T cells. J Allergy Clin Immunol  2010; 126(2): 280-9.
 [http://dx.doi.org/10.1016/j.jaci.2010.05.022] [PMID:  20624644]

[103]
Martin-Orozco N, Li Y, Wang Y, et al. Melanoma cells express ICOS ligand to promote the activation and expansion of T-regulatory cells. Cancer Res  2010; 70(23): 9581-90.
 [http://dx.doi.org/10.1158/0008-5472.CAN-10-1379] [PMID:  21098714]

[104]
Amatore F, Gorvel L, Olive D. Inducible Co-Stimulator (ICOS) as a potential therapeutic target for anti-cancer therapy. Expert Opin Ther Targets  2018; 22(4): 343-51.
 [http://dx.doi.org/10.1080/14728222.2018.1444753] [PMID:  29468927]

[105]
Roos A, Schilder-Tol EJM, Weening JJ, Aten J. Strong expression of CD134 (OX40), a member of the TNF receptor family, in a T helper 2-type cytokine environment. J Leukoc Biol  1998; 64(4): 503-10.
 [http://dx.doi.org/10.1002/jlb.64.4.503] [PMID:  9766631]

[106]
Croft M, So T, Duan W, Soroosh P. The significance of OX40 and OX40L to T-cell biology and immune disease. Immunol Rev  2009; 229(1): 173-91.
 [http://dx.doi.org/10.1111/j.1600-065X.2009.00766.x] [PMID:  19426222]

[107]
Jensen SM, Maston LD, Gough MJ, et al. Signaling through OX40 enhances antitumor immunity. Semin Oncol  2010; 37(5): 524-32.
 [http://dx.doi.org/10.1053/j.seminoncol.2010.09.013] [PMID:  21074068]

[108]
Yashiro T, Hara M, Ogawa H, Okumura K, Nishiyama C. Critical role of transcription Factor PU.1 in the function of the OX40L/TNFSF4 promoter in dendritic cells. Sci Rep  2016; 6(1): 34825.
 [http://dx.doi.org/10.1038/srep34825] [PMID:  27708417]

[109]
Peramuhendige P, Marino S, Bishop RT, et al. TRAF2 in osteotropic breast cancer cells enhances skeletal tumour growth and promotes osteolysis. Sci Rep  2018; 8(1): 39.
 [http://dx.doi.org/10.1038/s41598-017-18327-5] [PMID:  29311633]

[110]
Hildebrand JM, Yi Z, Buchta CM, Poovassery J, Stunz LL, Bishop GA. Roles of tumor necrosis factor receptor associated factor 3 (TRAF3) and TRAF5 in immune cell functions. Immunol Rev  2011; 244(1): 55-74.
 [http://dx.doi.org/10.1111/j.1600-065X.2011.01055.x] [PMID:  22017431]

[111]
Alves Costa Silva C, Facchinetti F, Routy B, Derosa L. New pathways in immune stimulation: Targeting OX40. ESMO Open  2020; 5(1): e000573.
 [http://dx.doi.org/10.1136/esmoopen-2019-000573] [PMID:  32392177]

[112]
Zhang X, Xiao X, Lan P, et al. OX40 costimulation inhibits Foxp3 expression and treg induction via BATF3-dependent and independent mechanisms. Cell Rep  2018; 24(3): 607-18.
 [http://dx.doi.org/10.1016/j.celrep.2018.06.052] [PMID:  30021159]

[113]
He Y, Zhang X, Jia K, et al. OX40 and OX40L protein expression of tumor infiltrating lymphocytes in non-small cell lung cancer and its role in clinical outcome and relationships with other immune biomarkers. Transl Lung Cancer Res  2019; 8(4): 352-66.
 [http://dx.doi.org/10.21037/tlcr.2019.08.15] [PMID:  31555511]

[114]
Ohshima Y, Yang LP, Uchiyama T, et al. OX40 costimulation enhances interleukin-4 (IL-4) expression at priming and promotes the differentiation of naive human CD4(+) T cells into high IL-4-producing effectors. Blood  1998; 92(9): 3338-45.
 [http://dx.doi.org/10.1182/blood.V92.9.3338] [PMID:  9787171]

[115]
Zhang Z, Zhong W, Hinrichs D, et al. Activation of OX40 augments Th17 cytokine expression and antigen-specific uveitis. Am J Pathol  2010; 177(6): 2912-20.
 [http://dx.doi.org/10.2353/ajpath.2010.100353] [PMID:  20952591]

[116]
Kashima J, Okuma Y, Hosomi Y, Hishima T. High Serum OX40 and OX40 Ligand (OX40L) levels correlate with reduced survival in patients with advanced lung adenocarcinoma. Oncology  2020; 98(5): 303-10.
 [http://dx.doi.org/10.1159/000505975] [PMID:  32097938]

[117]
Linch SN, McNamara MJ, Redmond WL. OX40 Agonists and Combination Immunotherapy: Putting the pedal to the metal. Front Oncol  2015; 5(FEB): 34.
 [http://dx.doi.org/10.3389/fonc.2015.00034] [PMID:  25763356]

[118]
Guttman-Yassky E, Pavel AB, Zhou L, et al. GBR 830, an anti-OX40, improves skin gene signatures and clinical scores in patients with atopic dermatitis. J Allergy Clin Immunol  2019; 144(2): 482-493.e7.
 [http://dx.doi.org/10.1016/j.jaci.2018.11.053] [PMID:  30738171]

[119]
Ronchetti S, Zollo O, Bruscoli S, et al. Frontline: GITR, a member of the TNF receptor superfamily, is costimulatory to mouse T lymphocyte subpopulations. Eur J Immunol  2004; 34(3): 613-22.
 [http://dx.doi.org/10.1002/eji.200324804] [PMID:  14991590]

[120]
Ronchetti S, Nocentini G, Petrillo M G, Riccardi C. CD8+ T Cells:
GITR matters. Sci World J  2012; 2012

[121]
Nocentini G, Riccardi C. GITR: A modulator of immune response and inflammation. Adv Exp Med Biol  2009; 647: 156-73.
 [http://dx.doi.org/10.1007/978-0-387-89520-8_11] [PMID:  19760073]

[122]
Nocentini G, Riccardi C. GITR: A multifaceted regulator of immunity belonging to the tumor necrosis factor receptor superfamily. Eur J Immunol  2005; 35(4): 1016-22.
 [http://dx.doi.org/10.1002/eji.200425818] [PMID:  15770698]

[123]
Shevach EM, Stephens GL. The GITR–GITRL interaction: Co-stimulation or contrasuppression of regulatory activity? Nat Rev Immunol  2006; 6(8): 613-8.
 [http://dx.doi.org/10.1038/nri1867] [PMID:  16868552]

[124]
Bae EM, Kim WJ, Suk K, et al. Reverse signaling initiated from GITRL induces NF-κB activation through ERK in the inflammatory activation of macrophages. Mol Immunol  2008; 45(2): 523-33.
 [http://dx.doi.org/10.1016/j.molimm.2007.05.013] [PMID:  17602748]

[125]
Snell LM, McPherson AJ, Lin GHY, et al. CD8 T cell-intrinsic GITR is required for T cell clonal expansion and mouse survival following severe influenza infection. J Immunol  2010; 185(12): 7223-34.
 [http://dx.doi.org/10.4049/jimmunol.1001912] [PMID:  21076066]

[126]
Kim YH, Shin SM, Choi BK, et al. Authentic GITR signaling fails to induce tumor regression unless Foxp3+ regulatory T cells are depleted. J Immunol  2015; 195(10): 4721-9.
 [http://dx.doi.org/10.4049/jimmunol.1403076] [PMID:  26423152]

[127]
Zhu MMT, Burugu S, Gao D, et al. Evaluation of glucocorticoid-induced TNF receptor (GITR) expression in breast cancer and across multiple tumor types. Mod Pathol  2020; 33(9): 1753-63.
 [http://dx.doi.org/10.1038/s41379-020-0550-z] [PMID:  32350416]

[128]
Cohen AD, Schaer DA, Liu C, et al. Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation. PLoS One  2010; 5(5): e10436.
 [http://dx.doi.org/10.1371/journal.pone.0010436] [PMID:  20454651]

[129]
Coe D, Begom S, Addey C, White M, Dyson J, Chai JG. Depletion of regulatory T cells by anti-GITR mAb as a novel mechanism for cancer immunotherapy. Cancer Immunol Immunother  2010; 59(9): 1367-77.
 [http://dx.doi.org/10.1007/s00262-010-0866-5] [PMID:  20480365]

[130]
Knee DA, Hewes B, Brogdon JL. Rationale for anti-GITR cancer immunotherapy. Eur J Cancer  2016; 67: 1-10.
 [http://dx.doi.org/10.1016/j.ejca.2016.06.028] [PMID:  27591414]

[131]
Sukumar S, Wilson DC, Yu Y, et al. Characterization of MK-4166, a clinical agonistic antibody that targets human GITR and inhibits the generation and suppressive effects of T regulatory cells. Cancer Res  2017; 77(16): 4378-88.
 [http://dx.doi.org/10.1158/0008-5472.CAN-16-1439] [PMID:  28611044]

[132]
Elgueta R, Benson MJ, de Vries VC, Wasiuk A, Guo Y, Noelle RJ. Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol Rev  2009; 229(1): 152-72.
 [http://dx.doi.org/10.1111/j.1600-065X.2009.00782.x] [PMID:  19426221]

[133]
Munroe ME, Bishop GA. A costimulatory function for T Cell CD40. J Immunol  2007; 178(2): 671-82.
 [http://dx.doi.org/10.4049/jimmunol.178.2.671]

[134]
Durie FH, Foy TM, Masters SR, Laman JD, Noelle RJ. The role of CD40 in the regulation of humoral and cell-mediated immunity. Immunol Today  1994; 15(9): 406-11.
 [http://dx.doi.org/10.1016/0167-5699(94)90269-0] [PMID:  7524518]

[135]
Aloui C, Prigent A, Sut C, Tariket S. The signaling role of CD40 ligand in platelet biology and in platelet component transfusion. Molecular sciences  2014; 15: 22342-64.

[136]
Daoussis D, Andonopoulos AP, Liossis S-NC. Targeting CD40L: a promising therapeutic approach. Clin Diagn Lab Immunol  2004; 11(4): 635-41.
 [PMID:  15242934]

[137]
Li R, Chen WC, Pang XQ, Hua C, Li L, Zhang XG. Expression of CD40 and CD40L in gastric cancer tissue and its clinical significance. Int J Mol Sci  2009; 10(9): 3900-17.
 [http://dx.doi.org/10.3390/ijms10093900] [PMID:  19865524]

[138]
Piechutta M, Berghoff AS. New emerging targets in cancer immunotherapy: The role of cluster of differentiation 40 (CD40/TNFR5). ESMO Open  2019; 4(e000510) (Suppl. 3): e000510.
 [http://dx.doi.org/10.1136/esmoopen-2019-000510] [PMID:  31275618]

[139]
Korniluk A, Kemona H, Dymicka-Piekarska V. Multifunctional CD40L: Pro- and anti-neoplastic activity. Tumour Biol  2014; 35(10): 9447-57.
 [http://dx.doi.org/10.1007/s13277-014-2407-x] [PMID:  25117071]

[140]
Ruvolo PP, Deng X, May WS. Phosphorylation of Bcl2 and regulation of apoptosis. Leukemia  2001; 15(4): 515-22.
 [http://dx.doi.org/10.1038/sj.leu.2402090] [PMID:  11368354]

[141]
Bishop GA, Moore CR, Xie P, Stunz LL, Kraus ZJ. TRAF Proteins in CD40 Signaling.In: Wu H, Ed  Advances in Experimental Medicine and Biology, TNF Receptor Associated Factors (TRAFs).  New York: New York, NY: Springer 2007; pp. 131-51.
 [http://dx.doi.org/10.1007/978-0-387-70630-6_11]

[142]
Rakhmilevich AL, Alderson KL, Sondel PM. T-cell-independent antitumor effects of CD40 ligation. Int Rev Immunol  2012; 31(4): 267-78.
 [http://dx.doi.org/10.3109/08830185.2012.698337] [PMID:  22804571]

[143]
Vonderheide RH. Prospect of targeting the CD40 pathway for cancer therapy. Clin Cancer Res  2007; 13(4): 1083-8.
 [http://dx.doi.org/10.1158/1078-0432.CCR-06-1893]

[144]
Kobata T, Jacquot S, Kozlowski S, Agematsu K, Schlossman SF, Morimoto C. CD27-CD70 interactions regulate B-cell activation by T cells. Proc Natl Acad Sci USA  1995; 92(24): 11249-53.
 [http://dx.doi.org/10.1073/pnas.92.24.11249] [PMID:  7479974]

[145]
Borst J, Hendriks J, Xiao Y. CD27 and CD70 in T cell and B cell activation. Curr Opin Immunol  2005; 17(3): 275-81.
 [http://dx.doi.org/10.1016/j.coi.2005.04.004] [PMID:  15886117]

[146]
Hendriks J, Xiao Y, Borst J. CD27 promotes survival of activated T cells and complements CD28 in generation and establishment of the effector T cell pool. J Exp Med  2003; 198(9): 1369-80.
 [http://dx.doi.org/10.1084/jem.20030916] [PMID:  14581610]

[147]
Claus C, Riether C, Schürch C, Matter MS, Hilmenyuk T, Ochsenbein AF. CD27 signaling increases the frequency of regulatory T cells and promotes tumor growth. Cancer Res  2012; 72(14): 3664-76.
 [http://dx.doi.org/10.1158/0008-5472.CAN-11-2791] [PMID:  22628427]

[148]
Jacobs J, Deschoolmeester V, Zwaenepoel K, et al. Unveiling a CD70-positive subset of cancer-associated fibroblasts marked by pro-migratory activity and thriving regulatory T cell accumulation. OncoImmunology  2018; 7(7): e1440167.
 [http://dx.doi.org/10.1080/2162402X.2018.1440167] [PMID:  29900042]

[149]
Katayama Y, Sakai A, Oue N, et al. A possible role for the loss of CD27-CD70 interaction in myelomagenesis. Br J Haematol  2003; 120(2): 223-34.
 [http://dx.doi.org/10.1046/j.1365-2141.2003.04069.x] [PMID:  12542479]

[150]
Chen D, Gerasimčik N, Camponeschi A. CD27 expression and its association with clinical outcome in children and adults with pro-B acute lymphoblastic leukemia. Blood Cancer J  2017; 7(6): e575.
 [http://dx.doi.org/10.1038/bcj.2017.55] [PMID:  28649984]

[151]
Turaj AH, Hussain K, Cox KL, et al. Antibody tumor targeting is enhanced by CD27 agonists through myeloid recruitment. Cancer Cell  2017; 32(6): 777-791.e6.
 [http://dx.doi.org/10.1016/j.ccell.2017.11.001] [PMID:  29198913]

[152]
Jacobs J, Deschoolmeester V, Zwaenepoel K, et al. CD70: An emerging target in cancer immunotherapy. Pharmacol Ther  2015; 155(July): 1-10.
 [http://dx.doi.org/10.1016/j.pharmthera.2015.07.007] [PMID:  26213107]

[153]
Wang K, Wei G, Liu D. CD19: A biomarker for B cell development, lymphoma diagnosis and therapy. Exp Hematol Oncol  2012; 1(1): 36.
 [http://dx.doi.org/10.1186/2162-3619-1-36] [PMID:  23210908]

[154]
Scheuermann RH, Racila E. CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy. Leuk Lymphoma  1995; 18(5-6): 385-97.
 [http://dx.doi.org/10.3109/10428199509059636] [PMID:  8528044]

[155]
Inwald DP, McDowall A, Peters MJ, et al. CD40 is constitutively expressed on platelets and provides a novel mechanism for platelet activation. Circ Res  2003; 92(9): 1041-8.
 [http://dx.doi.org/10.1161/01.RES.0000070111.98158.6C] [PMID:  12676820]

[156]
Brudno JN, Lam N, Vanasse D, et al. Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma. Nat Med  2020; 26(2): 270-80.
 [http://dx.doi.org/10.1038/s41591-019-0737-3] [PMID:  31959992]

[157]
Cheng J, Zhao L, Zhang Y, et al. Understanding the mechanisms of resistance to CAR T-Cell therapy in malignancies. Front Oncol  2019; 9(November): 1237.
 [http://dx.doi.org/10.3389/fonc.2019.01237] [PMID:  31824840]

[158]
van Zelm MC, Smet J, Adams B, et al. CD81 gene defect in humans disrupts CD19 complex formation and leads to antibody deficiency. J Clin Invest  2010; 120(4): 1265-74.
 [http://dx.doi.org/10.1172/JCI39748] [PMID:  20237408]

[159]
Davila ML, Brentjens RJ. CD19-Targeted CAR T cells as novel cancer immunotherapy for relapsed or refractory B-cell acute lymphoblastic leukemia. Clin Adv Hematol Oncol  2016; 14(10): 802-8.
 [PMID:  27930631]

[160]
Onea AS, Jazirehi AR. CD19 chimeric antigen receptor (CD19 CAR)-redirected adoptive T-cell immunotherapy for the treatment of relapsed or refractory B-cell Non-Hodgkin’s Lymphomas. Am J Cancer Res  2016; 6(2): 403-24.
 [PMID:  27186412]

[161]
Liu W, Peng B, Lu Y, Xu W, Qian W, Zhang JY. Autoantibodies to tumor-associated antigens as biomarkers in cancer immunodiagnosis. Autoimmun Rev  2011; 10(6): 331-5.
 [http://dx.doi.org/10.1016/j.autrev.2010.12.002] [PMID:  21167321]

[162]
Zhang JY, Casiano CA, Peng XX, Koziol JA, Chan EKL, Tan EM. Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens. Cancer Epidemiol Biomarkers Prev  2003; 12(2): 136-43.
 [PMID:  12582023]

[163]
Zhang JY, Looi KS, Tan EM. Identification of tumor-associated antigens as diagnostic and predictive biomarkers in cancer. Methods Mol Biol  2009; 520: 1-10.
 [http://dx.doi.org/10.1007/978-1-60327-811-9_1] [PMID:  19381943]

[164]
Heo CK, Bahk YY, Cho EW. Tumor-associated autoantibodies as diagnostic and prognostic biomarkers. BMB Rep  2012; 45(12): 677-85.
 [http://dx.doi.org/10.5483/BMBRep.2012.45.12.236] [PMID:  23261052]

[165]
Nishimura Y, Tomita Y, Yuno A, Yoshitake Y, Shinohara M. Cancer immunotherapy using novel tumor-associated antigenic peptides identified by genome-wide cDNA microarray analyses. Cancer Sci  2015; 106(5): 505-11.
 [http://dx.doi.org/10.1111/cas.12650] [PMID:  25726868]

[166]
Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med  2000; 6(4): 443-6.
 [http://dx.doi.org/10.1038/74704] [PMID:  10742152]

[167]
Wittrup KD. Antitumor antibodies can drive therapeutic T Cell responses. Trends Cancer  2017; 3(9): 615-20.
 [http://dx.doi.org/10.1016/j.trecan.2017.07.001] [PMID:  28867165]

[168]
Lewis JJ, Houghton AN. Definition of tumor antigens suitable for vaccine construction. Semin Cancer Biol  1995; 6(6): 321-7.
 [http://dx.doi.org/10.1016/1044-579X(95)90001-2] [PMID:  8938270]

[169]
Okabe H, Satoh S, Kato T, et al. Genome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarray: identification of genes involved in viral carcinogenesis and tumor progression. Cancer Res  2001; 61(5): 2129-37.
 [PMID:  11280777]

[170]
Soliman H, Mediavilla-Varela M, Antonia S. Indoleamine 2,3-Dioxygenase. Cancer J  2010; 16(4): 354-9.
 [http://dx.doi.org/10.1097/PPO.0b013e3181eb3343] [PMID:  20693847]

[171]
Badawy AAB. Kynurenine pathway of tryptophan metabolism: Regulatory and functional aspects. Int J Tryptophan Res  2017; 10(1)
 [http://dx.doi.org/10.1177/1178646917691938] [PMID:  28469468]

[172]
Mbongue J, Nicholas D, Torrez T, Kim NS, Firek A, Langridge W. The Role of Indoleamine 2, 3-Dioxygenase in immune suppression and autoimmunity. Vaccines   2015; 3(3): 703-29.
 [http://dx.doi.org/10.3390/vaccines3030703] [PMID:  26378585]

[173]
Lanser L, Kink P, Egger EM, et al. Inflammation-induced tryptophan breakdown is related with anemia, fatigue, and depression in cancer. Front Immunol  2020; 11(February): 249.
 [http://dx.doi.org/10.3389/fimmu.2020.00249] [PMID:  32153576]

[174]
Prendergast GC, Malachowski WJ, Mondal A, Scherle P, Muller AJ. Indoleamine 2,3-Dioxygenase and its therapeutic inhibition in cancer. Int Rev Cell Mol Biol  2018; 336: 175-203.
 [http://dx.doi.org/10.1016/bs.ircmb.2017.07.004] [PMID:  29413890]

[175]
Frumento G, Rotondo R, Tonetti M, Damonte G, Benatti U, Ferrara GB. Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. J Exp Med  2002; 196(4): 459-68.
 [http://dx.doi.org/10.1084/jem.20020121] [PMID:  12186838]

[176]
Nayak-Kapoor A, Hao Z, Sadek R, et al. Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors. J Immunother Cancer  2018; 6(1): 61.
 [http://dx.doi.org/10.1186/s40425-018-0351-9] [PMID:  29921320]

[177]
Fox JM, Sage LK, Huang L, et al. Inhibition of indoleamine 2,3-dioxygenase enhances the T-cell response to influenza virus infection. J Gen Virol  2013; 94(7): 1451-61.
 [http://dx.doi.org/10.1099/vir.0.053124-0] [PMID:  23580425]

[178]
Seeber A, Klinglmair G, Fritz J, et al. High IDO -1 expression in tumor endothelial cells is associated with response to immunotherapy in metastatic renal cell carcinoma. Cancer Sci  2018; 109(5): 1583-91.
 [http://dx.doi.org/10.1111/cas.13560] [PMID:  29498788]

[179]
Ye Z, Yue L, Shi J, Shao M, Wu T. Role of IDO and TDO in cancers and related diseases and the therapeutic implications. J Cancer  2019; 10(12): 2771-82.
 [http://dx.doi.org/10.7150/jca.31727] [PMID:  31258785]

[180]
Moon YW, Hajjar J, Hwu P, Naing A. Targeting the indoleamine 2,3-dioxygenase pathway in cancer. J Immunother Cancer  2015; 3(1): 51.
 [http://dx.doi.org/10.1186/s40425-015-0094-9] [PMID:  26674411]

[181]
Amobi A, Qian F, Lugade AA, Odunsi K. Tryptophan catabolism and cancer immunotherapy targeting IDO mediated immune suppression. Adv Exp Med Biol  2017; 1036: 129-44.
 [http://dx.doi.org/10.1007/978-3-319-67577-0_9] [PMID:  29275469]

[182]
Peng Z, Hu Y, Ren J, Yu N, Li Z, Xu Z. Circulating Th22 cells, as well as Th17 cells, are elevated in patients with renal cell carcinoma. Int J Med Sci  2021; 18(1): 99-108.
 [http://dx.doi.org/10.7150/ijms.47384] [PMID:  33390778]

[183]
Ivanova EA, Orekhov ANT. Helper lymphocyte subsets and plasticity in autoimmunity and cancer: An overview. BioMed Res Int  2015; 2015: 1-9.
 [http://dx.doi.org/10.1155/2015/327470] [PMID:  26583100]
Cite As
Current Cancer Therapy Reviews

Prominent Targets for Cancer Care: Immunotherapy Perspective

Abstract

Graphical Abstract
